Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma

This page shows the latest Kite Pharma news and features for those working in and with pharma, biotech and healthcare.

Celgene reaches $9bn agreement to buy Juno

Celgene reaches $9bn agreement to buy Juno

Acquires its blood cancer CAR-T candidate in the process

Latest news

  • Novartis gets speedy reviews for new Kymriah filings Novartis gets speedy reviews for new Kymriah filings

    The cell-based cancer immunotherapy was approved in the US last August for the ALL indication, shortly before CAR-T rival Kite Pharma (now part of Gilead Sciences) got a green ... benefit, while Yescarta costs $373, 000 for DLBCL - but the Swiss pharma

  • Gilead adds to CAR-T assets with Cell Design Labs buyout Gilead adds to CAR-T assets with Cell Design Labs buyout

    Gilead adds to CAR-T assets with Cell Design Labs buyout. Gains full control of the biotherapeutics firm following its acquisition of Kite Pharma. ... Just a few months after shelling out $12bn to buy CAR-T specialist Kite Pharma, Gilead Sciences is

  • Novartis files CAR-T therapy CTL109 in Europe Novartis files CAR-T therapy CTL109 in Europe

    Novartis is ploughing a new furrow in cancer immunotherapy along with other companies, and in particular Kite Pharma (now part of Gilead Sciences) which has just claimed US approval for its ... Kite was the first to file its new therapy in Europe,

  • Novartis moves swiftly with lymphoma filing for CAR-T Kymriah Novartis moves swiftly with lymphoma filing for CAR-T Kymriah

    Novartis moves swiftly with lymphoma filing for CAR-T Kymriah. Will go up against Kite Pharma's Yescarta if approved. ... Approval for DLBCL will up the ante in Novartis’rivalry with CAR-T developer Kite Pharma - now part of Gilead Sciences - which got

  • Alcon spin-out more likely but not imminent, says Novartis Alcon spin-out more likely but not imminent, says Novartis

    and subsuming ophthalmic drugs into the pharma division. ... was joined in the new category by Gilead/Kite Pharma’s Yescarta (axicabtagene ciloleucel) last week.

More from news
Approximately 14 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    The company hopes its $12bn acquisition of Kite Pharma (August 2017) will help it steal a march on the lucrative CAR-T market through its treatment for advanced lymphoma. ... The data this article was based on is available in full online:

  • Pharma deals continue to slide Pharma deals continue to slide

    Given big pharma’s reluctance to spend on M&A it is perhaps surprising that this month Gilead has announced the $11.9bn acquisition of Kite Pharma. ... Licensing . The most common licensing deal is big pharma licensing in from biotech.

  • Deal Watch January 2017 Deal Watch January 2017

    Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19). ... 160. Kite Pharma. Fosun Pharma. Formation of a JV. Autologous T-cell therapies in cancer.

  • Deal Watch November 2016 Deal Watch November 2016

    As Juno wrestles with bad publicity and a depressed share price, Novartis and Kite Pharma, also active in the CAR T cell space, presented promising data at the ASH meeting for ... licence. 115.5. Medivir | BioPhausia/ Karo Pharma. business with 13

  • Deal Watch June 2016 Deal Watch June 2016

    licence. 770. Teva and Allergan/ Mayne Pharma. US generic portfolio of 37 approved and 5 FDA filed products. ... licence. 80. Cell Design Labs/ Kite Pharma. 'On/off switch' technology to regulate activity of engineered CAR T-cells for AML, certain B-cell

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • How do you define a biotech company?

    Johnson &Johnson and Pfizer are two of the largest pharma companies in the world by revenue but both have numerous biological therapies. ... This approach is particularly apparent in some of the recent examples of technology pioneered by biotech

  • Random42 Scientific Communication

    We have worked with 24 of the top 25 pharma companies creatingslide kits and scientific illustrations. ... Galderma. Genentech. Gilead. GlaxoSmithKline. Heron Therapeutics. Janssen. Keryx Biopharmaceuticals. Kite Pharma.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics